Gilead Sciences Q3 Adj $2.29 Beats $1.92 Estimate, Sales $7.10B Beat $6.80B Estimate
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences reported Q3 earnings of $2.29 per share, beating the analyst consensus estimate of $1.92 by 19.27%. This is a 20.53% increase from the same period last year. The company also reported quarterly sales of $7.10 billion, beating the analyst consensus estimate of $6.80 billion by 4.41%. This is a 0.82% increase from the same period last year.
November 07, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences' Q3 earnings and sales beat estimates, indicating a strong financial performance. This could potentially lead to a positive impact on the company's stock.
Gilead Sciences reported better than expected Q3 earnings and sales, which is typically a positive signal for the company's stock. Investors often react positively to earnings beats as it indicates the company is performing well financially.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100